MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance
Maria Beatrice Arasi, Gabriele De Luca, Laura Chronopoulou, Francesca Pedini, Eleonora Petrucci, Michela Flego, Annarita Stringaro, Marisa Colone, Luca Pasquini, Massimo Spada, Valentina Lulli, Maria Chiara Perrotta, George A. Calin, Cleofe Palocci, Mauro Biffoni, Federica Felicetti, Nadia Felli
Topics & Concepts
MelanomaCancer researchIn vivoPI3K/AKT/mTOR pathwayTargeted therapyImmunotherapyMetastasisProtein kinase BMedicineCancerChemistryImmune systemPharmacologyImmunologyBiologyInternal medicineSignal transductionBiochemistryBiotechnologyImmunotherapy and Immune ResponsesRNA Interference and Gene DeliveryProtein Degradation and Inhibitors